FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790672246> ?p ?o ?g. }

• W2790672246 endingPage "1226" @default.
• W2790672246 startingPage "1220" @default.
• W2790672246 abstract "Paclitaxel is currently only available as an intravenous (i.v.) formulation. DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated comparable efficacy, safety, and pharmacokinetics to i.v. paclitaxel as a second-line therapy in patients with advanced gastric cancer (AGC). DREAM is a multicenter, open-label, prospective, randomized phase III study of patients with histologically/cytologically confirmed, unresectable/recurrent AGC after first-line therapy failure.Patients were randomized 1 : 1 to DHP107 (200 mg/m2 orally twice daily days 1, 8, 15 every 4 weeks) or i.v. paclitaxel (175 mg/m2 day 1 every 3 weeks). Patients were stratified by Eastern Cooperative Oncology Group performance status, disease status, and prior treatment; response was assessed (Response Evaluation Criteria in Solid Tumors) every 6 weeks. Primary end point: non-inferiority of progression-free survival (PFS); secondary end points: overall response rate (ORR), overall survival (OS), and safety. For the efficacy analysis, sequential tests for non-inferiority were carried out, first with a non-inferiority margin of 1.48, then with a margin of 1.25.Baseline characteristics were balanced in the 236 randomized patients (n = 118 per arm). Median PFS (per-protocol) was 3.0 (95% CI 1.7-4.0) months for DHP107 and 2.6 (95% CI 1.8-2.8) months for paclitaxel (hazard ratio [HR] = 0.85; 95% CI 0.64-1.13). A sensitivity analysis on PFS using independent central review showed similar results (HR = 0.93; 95% CI 0.70-1.24). Median OS (full analysis set) was 9.7 (95% CI 7.1 - 11.5) months for DHP107 versus 8.9 (95% CI 7.1-12.2) months for paclitaxel (HR = 1.04; 95% CI 0.76-1.41). ORR was 17.8% for DHP107 (CR 4.2%; PR 13.6%) versus 25.4% for paclitaxel (CR 3.4%; PR 22.0%). Nausea, vomiting, diarrhea, and mucositis were more common with DHP107; peripheral neuropathy was more common with paclitaxel. There were only few Grade≥3 adverse events, most commonly neutropenia (42% versus 53%); febrile neutropenia was reported infrequently (5.9% versus 2.5%). No hypersensitivity reactions occurred with DHP107 (paclitaxel 2.5%).DHP107 as a second-line treatment of AGC was non-inferior to paclitaxel for PFS; other efficacy and safety parameters were comparable. DHP107 is the first oral paclitaxel with proven efficacy/safety for the treatment of AGC.NCT01839773." @default.
• W2790672246 created "2018-03-29" @default.
• W2790672246 creator A5006335187 @default.
• W2790672246 creator A5013026650 @default.
• W2790672246 creator A5014474281 @default.
• W2790672246 creator A5024676627 @default.
• W2790672246 creator A5026250495 @default.
• W2790672246 creator A5038041478 @default.
• W2790672246 creator A5039375128 @default.
• W2790672246 creator A5047473026 @default.
• W2790672246 creator A5050625196 @default.
• W2790672246 creator A5051270409 @default.
• W2790672246 creator A5062301570 @default.
• W2790672246 creator A5066449485 @default.
• W2790672246 creator A5071195069 @default.
• W2790672246 creator A5074082836 @default.
• W2790672246 creator A5074290142 @default.
• W2790672246 creator A5082143898 @default.
• W2790672246 creator A5085952795 @default.
• W2790672246 creator A5091503999 @default.
• W2790672246 date "2018-05-01" @default.
• W2790672246 modified "2023-10-18" @default.
• W2790672246 title "Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy" @default.
• W2790672246 cites W1836451026 @default.
• W2790672246 cites W1905936368 @default.
• W2790672246 cites W1935541780 @default.
• W2790672246 cites W1938913042 @default.
• W2790672246 cites W1965697619 @default.
• W2790672246 cites W1984820569 @default.
• W2790672246 cites W2019607817 @default.
• W2790672246 cites W2032167680 @default.
• W2790672246 cites W2033203975 @default.
• W2790672246 cites W2040709429 @default.
• W2790672246 cites W2049301565 @default.
• W2790672246 cites W2053026268 @default.
• W2790672246 cites W2061333709 @default.
• W2790672246 cites W2083240168 @default.
• W2790672246 cites W2097820456 @default.
• W2790672246 cites W2116966392 @default.
• W2790672246 cites W2168709649 @default.
• W2790672246 cites W2184694295 @default.
• W2790672246 cites W2588739288 @default.
• W2790672246 doi "https://doi.org/10.1093/annonc/mdy055" @default.
• W2790672246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29438463" @default.
• W2790672246 hasPublicationYear "2018" @default.
• W2790672246 type Work @default.
• W2790672246 sameAs 2790672246 @default.
• W2790672246 citedByCount "33" @default.
• W2790672246 countsByYear W27906722462016 @default.
• W2790672246 countsByYear W27906722462018 @default.
• W2790672246 countsByYear W27906722462019 @default.
• W2790672246 countsByYear W27906722462020 @default.
• W2790672246 countsByYear W27906722462021 @default.
• W2790672246 countsByYear W27906722462022 @default.
• W2790672246 countsByYear W27906722462023 @default.
• W2790672246 crossrefType "journal-article" @default.
• W2790672246 hasAuthorship W2790672246A5006335187 @default.
• W2790672246 hasAuthorship W2790672246A5013026650 @default.
• W2790672246 hasAuthorship W2790672246A5014474281 @default.
• W2790672246 hasAuthorship W2790672246A5024676627 @default.
• W2790672246 hasAuthorship W2790672246A5026250495 @default.
• W2790672246 hasAuthorship W2790672246A5038041478 @default.
• W2790672246 hasAuthorship W2790672246A5039375128 @default.
• W2790672246 hasAuthorship W2790672246A5047473026 @default.
• W2790672246 hasAuthorship W2790672246A5050625196 @default.
• W2790672246 hasAuthorship W2790672246A5051270409 @default.
• W2790672246 hasAuthorship W2790672246A5062301570 @default.
• W2790672246 hasAuthorship W2790672246A5066449485 @default.
• W2790672246 hasAuthorship W2790672246A5071195069 @default.
• W2790672246 hasAuthorship W2790672246A5074082836 @default.
• W2790672246 hasAuthorship W2790672246A5074290142 @default.
• W2790672246 hasAuthorship W2790672246A5082143898 @default.
• W2790672246 hasAuthorship W2790672246A5085952795 @default.
• W2790672246 hasAuthorship W2790672246A5091503999 @default.
• W2790672246 hasBestOaLocation W27906722461 @default.
• W2790672246 hasConcept C121608353 @default.
• W2790672246 hasConcept C126322002 @default.
• W2790672246 hasConcept C141071460 @default.
• W2790672246 hasConcept C143998085 @default.
• W2790672246 hasConcept C168563851 @default.
• W2790672246 hasConcept C203092338 @default.
• W2790672246 hasConcept C207103383 @default.
• W2790672246 hasConcept C2776694085 @default.
• W2790672246 hasConcept C2777292972 @default.
• W2790672246 hasConcept C2779984678 @default.
• W2790672246 hasConcept C31760486 @default.
• W2790672246 hasConcept C44249647 @default.
• W2790672246 hasConcept C71924100 @default.
• W2790672246 hasConcept C90924648 @default.
• W2790672246 hasConceptScore W2790672246C121608353 @default.
• W2790672246 hasConceptScore W2790672246C126322002 @default.
• W2790672246 hasConceptScore W2790672246C141071460 @default.
• W2790672246 hasConceptScore W2790672246C143998085 @default.
• W2790672246 hasConceptScore W2790672246C168563851 @default.
• W2790672246 hasConceptScore W2790672246C203092338 @default.
• W2790672246 hasConceptScore W2790672246C207103383 @default.
• W2790672246 hasConceptScore W2790672246C2776694085 @default.
• W2790672246 hasConceptScore W2790672246C2777292972 @default.

• next